| Symbol | RAPP |
|---|---|
| Name | RAPPORT THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1325 BOYLSTON STREET,,SUITE 401, BOSTON, Massachusetts, 02215, United States |
| Telephone | 857-321-8020 |
| Fax | — |
| — | |
| Website | https://www.rapportrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002012593 |
| Description | Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. Additional info from NASDAQ: |
📋 KRISHNASWAMY YELESWARAM (Officer) plans to sell 37K shares of Rapport Therapeutics, Inc. (at $49.33 each, total $1.8M) Filed: Aug 25, 2026 | ID: 008670
Read more📋 KRISHNASWAMY YELESWARAM (Officer) plans to sell 11K shares of Rapport Therapeutics, Inc. (at $48.24 each, total $553K) Filed: Aug 24, 2026 | ID: 008594
Read moreRapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
Read moreYeleswaram Krishnaswamy 🔴 sold 404 shares of Rapport Therapeutics, Inc. (RAPP) at $49.90 Transaction Date: Aug 19, 2026 | Filing ID: 359189
Read more📋 KRISHNASWAMY YELESWARAM (Officer) plans to sell 2K shares of Rapport Therapeutics, Inc. (at $49.01 each, total $103K) Filed: Aug 19, 2026 | ID: 008426
Read moreNew Form SCHEDULE 13G/A - Rapport Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352285 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G/A - Rapport Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003693 <b>Size:</b> 9 KB
Read moreCeesay Abraham 🔴 sold 51.5K shares of Rapport Therapeutics, Inc. (RAPP) at $48.62 ($2.4M) Transaction Date: Aug 10, 2026 | Filing ID: 346995
Read moreCeesay Abraham 🔴 sold 2.2K shares of Rapport Therapeutics, Inc. (RAPP) at $42.73 Transaction Date: Jul 27, 2026 | Filing ID: 323637
Read moreCeesay Abraham 🔴 sold 8.2K shares of Rapport Therapeutics, Inc. (RAPP) at $40.57 Transaction Date: Jul 14, 2026 | Filing ID: 304786
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07594119 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With … | Phase3 | Focal Seizure | Recruiting | 2026-08-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT07563881 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With … | Phase3 | Focal Seizure | Recruiting | 2026-06-05 | 2029-09-01 | ClinicalTrials.gov |
| NCT07219407 | A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Foc… | Phase2 | Focal Epilepsy | Recruiting | 2025-12-15 | 2028-02-03 | ClinicalTrials.gov |
| NCT07046494 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With … | Phase2 | Bipolar 1 Disorder | Active_Not_Recruiting | 2025-07-25 | 2026-10-01 | ClinicalTrials.gov |
| NCT06377930 | Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With … | Phase2 | Focal Onset Seizures | Completed | 2024-10-10 | 2025-09-26 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | ACTIVE_NOT_RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | ACTIVE_NOT_RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07594119 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| Placebo | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE3 | Focal Seizure | NOT_YET_RECRUITING | NCT07563881 |
| RAP-219 | Other | Phase PHASE2 | Focal Epilepsy | RECRUITING | NCT07219407 |
| RAP-219 | Other | Phase PHASE2 | Focal Onset Seizures | COMPLETED | NCT06377930 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | Other | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| Placebo | OTHER | Phase PHASE2 | Bipolar 1 Disorder | RECRUITING | NCT07046494 |
| RAP-219 | DRUG | Phase PHASE2 | Focal Epilepsy | RECRUITING | NCT07219407 |